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The expression of the prion protein (PrP) is essential for transmissible spongiform encephalopathy (TSE) or prion
diseases to occur, but the underlying mechanism of infection remains unresolved. To address the hypothesis that
glycosylation of host PrP is a major factor influencing TSE infection, we have inoculated gene-targeted transgenic mice
that have restricted N-linked glycosylation of PrP with three TSE strains. We have uniquely demonstrated that mice
expressing only unglycosylated PrP can sustain a TSE infection, despite altered cellular location of the host PrP.
Moreover we have shown that brain material from mice infected with TSE that have only unglycosylated PrPSc is
capable of transmitting infection to wild-type mice, demonstrating that glycosylation of PrP is not essential for
establishing infection within a host or for transmitting TSE infectivity to a new host. We have further dissected the
requirement of each glycosylation site and have shown that different TSE strains have dramatically different
requirements for each of the glycosylation sites of host PrP, and moreover, we have shown that the host PrP has a
major role in determining the glycosylation state of de novo generated PrPSc.
Citation: Tuzi NL, Cancellotti E, Baybutt H, Blackford L, Bradford B, et al. (2008) Host PrP glycosylation: a major factor determining the outcome of prion infection. PLoS Biol
6(4): e100. doi:10.1371/journal.pbio.0060100
Introduction
Transmissible spongiform encephalopathies (TSEs), or
prion diseases, are fatal neurodegenerative diseases that
include scrapie in sheep, bovine spongiform encephalopathy
(BSE) in cattle, chronic wasting disease (CWD) in deer and elk
and Creutzfeldt-Jakob disease (CJD) in humans. The host-
encoded glycophosphatidylinositol anchored prion protein,
PrPC, is essential for the development of TSE disease [1], and
a common feature of these diseases is the accumulation of
PrPSc in the brain, an abnormal form of PrPC, which displays
partial resistance to proteinase K (PK) digestion. This
accumulation is considered to arise via conversion of PrPC
to PrPSc [2], and PrPSc has been proposed to be the infectious
agent. If this is indeed the case, it is not clear how a protein
alone can encipher TSE strain information resulting in
different incubation times and targeting of pathological
lesions in the brain, but it has been suggested that differences
in glycosylation and/or conformation [3–6] of PrP could
account for these different properties.
PrP has two potential sites for N-linked glycosylation,
which are variably occupied, producing di-, mono-, and
unglycosylated PrP [7]. The diversity in glycosylation, com-
bined with the complexity of added sugars, results in a large
number of glycosylated forms of PrP [8]. These different
glycoforms of host PrP have been proposed as a mechanism
to determine the targeting of TSE strains to speciﬁc brain
regions [6]. Moreover, PrP glycoform analysis in the infected
host (ratios of di- and monoglycosylated PrPSc, as well as the
relative mobility of unglycosylated PrPSc) is increasingly used
as a means of distinguishing between TSE strains [9,10] and
for identifying and classifying newly emerging strains [11,12].
However, the signiﬁcance of different glycosylated forms of
PrP in the normal function of PrP as well as the disease
process is not understood. To investigate the involvement of
host PrP glycosylation on TSE disease susceptibility and
pathology following infection with different TSE strains, we
have used our gene-targeted transgenic mice with restricted
host PrP glycosylation and inoculated them intracerebrally
with three TSE strains.
Three inbred lines of gene-targeted mice, carrying muta-
tions at the ﬁrst, second, or both PrP N-linked glycosylation
sites—referred to as G1 (N180T), G2 (N196T), and G3
(N180T-N196T) mouse lines, respectively [13]—were used in
these experiments. The gene targeting approach ensures that
the altered PrP allele remains in the correct genomic location
under control of the endogenous promoter [14]. Importantly,
this approach allows each line of mice to be compared, and
thus the effect of the loss of each glycosylation site on disease
pathogenesis can be analysed directly.
Western blot analysis has demonstrated that both G1 and
G2 lines lack diglycosylated, but express mono- and un-
glycosylated PrP, whereas G3 mice only express unglycosy-
lated PrP [13]. PrP in the mutant mice has been shown to have
a similar cellular localisation in G1 and G2 mice to that of
wild type, whereas G3 mice, which lack all PrP N-linked
carbohydrates, have been demonstrated to have mainly
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intracellular PrP [13]. Despite differences in intracellular
localisation, mono- and unglycosylated PrP levels in the brain
are similar to those in wild type [13]. Here we establish, using
these unique lines of mice, that although host PrP glyco-
sylation is not essential to support TSE disease, it can have a
profound effect on capacity of TSE strains to infect the host.
Furthermore we demonstrate in vivo that glycosylation of
PrPSc is not essential for TSE strain to transmit infectivity.
Results
Three homozygous lines (G1/G1, G2/G2, and G3/G3,
subsequently referred to as G1, G2, and G3 respectively),
together with 129/Ola wild-type mice (which acted as
controls, because the gene-targeted mice are inbred lines
on a 129/Ola background), were infected intracerebrally (i.c.)
with the TSE strains 79A and ME7, which are classiﬁed as low
and medium glycosylated strains, respectively, according to
their glycoform analysis based upon the ratio of the diglycosyl
and monoglycosyl bands by Western blotting [15]. Each of
these lines of mice was shown to respond in strikingly
different ways to infection with each TSE strain.
G3 Mice Expressing Unglycosylated PrP Differ in Their
Response to Various TSE Strains
G3 mice were susceptible to 79A infection, with clinical
TSE and spongiform degeneration of the brain being
observed in 4/21 animals (Table 1). However, although only
four mice presented with clinical TSE disease, with consid-
erably longer and wider range of incubation times (435 6 92
d) compared with wild-type mice (148 6 2.6 d), Western blot
analysis of six brains all demonstrated PK-resistant PrP,
whether or not clinical disease was observed (Figure 1A).
Furthermore, immunohistochemical analysis of brains re-
vealed variation in the amount of PrP immunopositivity
amongst cases with some animals without clinical signs
showing widespread accumulation of PrP in the cerebrum
(Figure 2A and 2B), suggesting that a subclinical disease was
also present in the G3 animals. Thus, 79A can infect
transgenic mice in the absence of glycosylated host PrP, but
this lack of glycosylation dramatically lengthens the incuba-
tion time of disease suggesting that glycosylation of host PrP
facilitates infection by 79A.
To establish whether the brains of G3 79A-inoculated mice
carried infectivity, brain homogenates from one clinically
positive (incubation period 456 d) and one subclinical G3
mouse (incubation period 722 d; i.e. clinically negative but
positive by immunohistochemistry and showing spongiform
degeneration of the brain) were used to inoculate wild-type
mice i.c.. For comparison, brain homogenate from a 79A
inoculated wild-type (129/Ola) control mouse was also used to
i.c. inoculate another group of wild-type mice. The brain
extracts from the two 79A/G3 mice and the one 79A/129/Ola
mouse were found to contain TSE infectivity (Table 2). The
clinically positive 79A/G3 brain homogenate resulted in an
incubation period of 197 d (67.6), whereas the clinically
negative 79A/G3 brain generated a shorter incubation time
(164 6 2.2 d), but both G3 brain homogenates produced
slightly longer incubation periods that that resulting from
79A/129/Ola (137 6 1.1 d). Western blot analysis of recipient
mouse brains revealed the presence of di-, mono-, and
unglycosylated PrPSc despite the absence of di- and mono-
Table 1. Incubation Periods of Wild-Type and Glycosylation Mutant Mice Infected with TSE Strains
Genotype TSE Strain Number Clinþ/Total Number of.Animals Incubation Period (Days 6 SEM) PrP Deposition Plaques
129/Ola 79A 24/24 148 (62.6) þþþþ –
G1/G1 79A 5/5 194 (621) þþþþ –
G2/G2 79A 12/12 167 (69.3) þþþþ þ
G3/G3 79A 4/21 435 (692) * þ þ
129/Ola ME7 21/21 163 (62) þþþþ –
G1/G1 ME7 0/16 .600 – –
G2/G2 ME7 14/14 160 (62.5) þþþþ þ
G3/G3 ME7 0/18 .700 – þ
129/Ola 301C 12/12 166 (61.5) þþþ –/þ
G2/G2 301C 12/15 354 (65.3) þþþþ þ
Levels of PrP deposition in the brains of clinically positive mice is reported with a range from minimum (–) to maximum (þþþþ) level of PrP observed, except *, which indicates more
extensive deposition of PrP detected in the clinically negative 79A infected G3 mice that had a PrP (þþþþ) deposition score and a (þ) plaque score. Observation of plaques formation is also
reported in some mouse brains (þ) but not in others (–). (–/þ) indicates where plaques were smaller in the wild-type compared to the transgenic mouse line.
doi:10.1371/journal.pbio.0060100.t001
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Author Summary
In prion infection, disease requires the presence of the endogenous
host-encoded prion protein, PrP. PrP is a glycoprotein (modified by
the addition of sugar molecules) with two consensus sites for sugars
to attach. Different PrP forms are usually observed: one diglycosy-
lated, two different monoglycosylated, and one unglycosylated.
How PrP glycosylation influences prion infection remains obscure.
We have used three different murine transgenic models, developed
with the gene-replacement technique, to investigate each glycotype
of PrP contribution to prion diseases, or transmissible spongiform
encephalopathies (TSEs). For this purpose, mice expressing mono-
or unglycosylated PrP were challenged with different prion strains.
Remarkably, we found that glycosylation of host PrP is not
mandatory for TSE infection, because mice expressing only
unglycosylated PrP were susceptible to infection and able to
transmit the disease to other animals. However, we also show that
host PrP glycosylation can modulate the infectious process, since
strains differ in their ability to infect hosts with restricted PrP
glycosylation. These results elucidate the role of glycosylation in
prion infection and in particular demonstrate that strains need
sugars at specific sites of host PrP to successfully induce prion
disease.
glycosylated PrPSc in 79A inoculated G3 mouse brain
(unpublished data). These data indicate that glycosylated
PrPSc is not a prerequisite for the transmission of infectivity.
In contrast, G3 mice inoculated with ME7 did not show
clinical signs of TSE disease or spongiform degeneration in
the brain as determined by lesion proﬁling and were thus
scored as pathologically negative [16]. Brains from selected
animals analysed by Western blotting showed no PK-resistant
PrP (Figure 1B) up to 740 d post inoculation (Table 1).
Despite the lack of these indicators of TSE disease, brains of a
number of animals showed PrP-positive plaques in the
vicinity of the corpus callosum and, in one case, adjacent to
the lateral ventricle; diffuse PrP deposits were not detected
(Figure 2C and 2D). Thioﬂavin-S–treated brain sections
conﬁrmed the presence of PrP amyloid plaques in 79A-
(Figure 2G) and ME7-inoculated G3 mice (Figure 2I). To
determine whether the presence of the PrP amyloid plaques
was in response to TSE inoculation rather than an innate
ability of G3 mice to form plaques, age-matched G3 mice (24
animals in total) that were injected with brain homogenates
from wild-type controls were examined but found to have no
PrP accumulation in the brain (unpublished data). In
addition, in agreement with previous studies [13], PrP
accumulation was not observed in older (600 d) uninjected
G3 mice. Therefore, the PrP accumulation in the brain of the
mice inoculated with 79A and ME7 was clearly in response to
inoculation with a TSE agent rather than due to any effect of
the mutation in host PrP per se. Whether this PrP
accumulation is associated with infectivity requires further
subpassage of G3/ME7 brains; however, tissue was not
available from this experiment to carry out this subpassage
and therefore will be examined in future studies.
G2 Mice Differ in Their Response to Scrapie or BSE-Derived
Strains
In contrast to G3 mice, all G2 mice were found to develop
clinical signs of disease when inoculated with ME7 and
presented with similar incubation periods to wild-type
controls (160 6 2.5 d and 163 62 d, respectively) (Table 1).
Spongiform degeneration, determined by lesion proﬁle
analysis, of G2 mouse brains was comparable to wild-type
mice both in the distribution and degree of vacuolation
(Figure 3A). Wide spread, ﬁne punctuate, coarse, and plaque-
like PrP immunopositive deposits were detected in ME7-
infected animals (Figure 4A). Mono- and unglycosylated PrPSc
was detected by Western blot analysis in brains of ME7-
inoculated G2 mice, whereas di-, mono- and unglycosylated
PrPSc was detectable in wild-type, inoculated mice (Figure
1C).
G2 mice were also shown to be susceptible to TSE disease
when inoculated with 79A, but whereas the incubation time
with ME7 was similar to that in wild-type mice, with 79A,
incubation time was signiﬁcantly prolonged (167 6 9.3 d for
G2/79A and 148 6 2.6 d for 79A/129/Ola) (Table 1). Spongi-
form degeneration of G2 mouse brains was also found to be
comparable to wild-type mice (Figure 3B). Immunohisto-
chemical analysis of selected 79A-inoculated G2 mouse brains
revealed variable amounts of ﬁne punctuate and plaque-like
PrP depositions in the cerebrum (Figure 4B). By Western blot
analysis, mono- and unglycosylated PrPSc was detected in
brains of 79A-inoculated G2 mice, whereas di-, mono-, and
unglycosylated PrPSc was detectable in wild-type, inoculated
mice (Figure 1D). To determine whether the brains of 79A-
inoculated G2 mice had TSE infectivity, despite the lack of
diglycosylated PrPSc, wild-type mice were inoculated with
brain homogenate from 79A-inoculated G2 and wild-type
control mice. All mice were found to be susceptible to TSE
disease with two independent 79A/G2 brain homogenates
producing incubation times of 150 d (63.4) and 159 d (61.2)
compared to 79A/129/Ola brain homogenate resulting in a
slightly shorter incubation period of 140 d (61.9) (Table 2).
The pattern and degree of spongiform degeneration in all
subpassage cases, as determined by lesion proﬁle analysis [16],
were found to be comparable (unpublished data). Western
Figure 1. Western Blot Analysis of Brains from TSE Inoculated
Glycosylation Mutant Mice
Brain homogenates were treated with or without PK as indicated prior to
SDS PAGE analysis.
(A) G3 and wild-type animals inoculated with 79A. Lanes 1–2: 129/Ola
wild-type mice clinically (clin) positive/pathologically (path) positive;
lanes 3–4: G3 mice clin positive/path positive; lanes 5–6: G3 mice clin
negative/path positive.
(B) G3 and wild-type animals inoculated with ME7. Lanes 1–2: 129/Ola
mice clin positive/path positive; lanes 3–4: G3 mice clin negative/path
negative with no plaques; lanes 5–6: G3 mice clin negative/path negative
with plaques.
(C) G2 and wild-type animals inoculated with ME7. Lanes 1–2: 129/Ola;
lanes 3–6: G2 mice, brains positive for plaques. All animals clin positive/
path positive.
(D) G2 and wild-type animals inoculated with 79A. Lanes 1–2: 129/Ola
mice; lanes 3–6: G2 mice. All animals clin positive/path positive.
(E) G2 and wild-type animals inoculated with 301C. Lanes 1–2: 129/Ola
mice; lanes 3–6: G2 mice brains positive for plaques. All animals clin
positive/path positive.
(F) G1 and wild-type animals inoculated with 79A. Lanes 1–2: 129/Ola
mice; lanes 3–6: G1 mice. All animals clin positive/path positive. Lanes 1–
4: 3-min exposure; lanes 5–6: 10-min exposure.
Molecular weight markers indicated in KDa. Wild-type (Wt) mice are 129/
Ola mice. Monoclonal antibody 7A12 (kindly provided by M.-S. Sy) was
used for immunodetection of PrP.
doi:10.1371/journal.pbio.0060100.g001
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Figure 2. Immunohistochemical Analysis of Brain from G3 Mice Inoculated with TSE Strains 79A or ME7
Sections from the cerebrum and cerebellum were immunostained for PrP with monoclonal antibody 6H4 and analysed by light microscopy using a
Nikon Eclipse E 800 microscope.
PLoS Biology | www.plosbiology.org April 2008 | Volume 6 | Issue 4 | e1000875
Role of Glycosylation in TSE Infection
blot analysis revealed the glycosylation pattern of the PrPSc in
the recipient mouse brain to possess di-, mono-, and
unglycosylated PrPSc (Figure 5B) despite the inoculum
possessing only mono- and unglycosylated PrPSc (Figure 5A).
Moreover, the glycosylation pattern of the original Wt/79A
inoculum was not changed after passage through G2 mice.
The comparison of the electrophoretic mobility of the 79A in
wild-type animals before and after passage through G2 mice
revealed the same glycotype with a predominant monoglyco-
sylated band (Figure 5C).
To investigate this effect with another strain of agent,
subpassage was performed from clinical positive G2/ME7
brains into wild-type animals. Western blot analysis of
recipient wild-type mice also showed fully glycosylated PrPSc
in the brain of the recipient mice, despite the inoculum
having only mono- and unglycosylated PrPSc (Figure 5D and
5E). Furthermore, similarly to the 79A strain, the original Wt/
ME7 glycosylation pattern was maintained after passage in G2
mice (Figure 5F). Therefore, it is clear that the ability to
generate diglycosylated PrPSc in response to TSE infection
does not depend on the presence of the diglycosylated species
of PrPSc in the infecting inoculum.
We originally chose the 79A and ME7 strains of TSE for use
in this study, because glycoform ratio analysis had revealed
them to have a different predominance of mono- and
diglycosylated PrPSc; with 79A predominantly monoglycosy-
lated, whereas ME7 was more equally di- and monoglycosy-
lated in wild-type mice [4]. Since the disease proﬁles observed
in G2 mice that were infected with ME7 and 79A were similar
to those observed in wild-type mice, with the exception of
slightly prolonged incubation times in G2/79A mice, we
decided to analyse the effect of the second glycosylation site
of PrP with a further TSE strain having a different glycoform
ratio. For this purpose we inoculated G2 mice and wild-type
mice intracerebrally with the BSE mouse-adapted TSE strain
301C, which has a predominance of diglycosylated PrPSc [15].
In contrast to ME7 and 79A, a very prolonged incubation
time was observed in the 301C inoculated G2 mice (354 6 5.3
d) compared to wild-type mice (166 6 1.5 d). However,
despite the prolonged incubation time in the 301C-inocu-
lated G2 mice, the overall pattern of spongiform degener-
ation was similar to that observed in wild-type mice (Figure
3C). Analysis by immunohistochemistry showed wide spread,
plaque-like, and ﬁne punctuate PrP deposits in G2 mice in
the cerebrum and cerebellum (Figure 4E and 4F), and mono-
and unglycosylated PrPSc was detected by Western blot
(Figure 1E). These experiments clearly show that this BSE-
derived strain does not require diglycosylated host PrP (the
predominant characteristic of the glycoform used to identify
BSE strains) to be pathogenic; however, the presence of
sugars at N196 of host PrP would appear to allow more
efﬁcient progression of TSE disease, because the time taken
to reach terminal disease is dramatically shorter in wild-type
mice having normal PrPC glycosylation. The importance of
the presence of glycans at N196 for efﬁcient TSE disease
progression is therefore clearly TSE strain dependent.
G1 Mice Are Susceptible to 79A, but Are Resistant to ME7,
Strain Infection
Having established that the absence of glycans at the
second glycosylation site of host PrP can inﬂuence PrP
deposition and incubation period, albeit in a strain-depend-
ent manner, we next investigated the importance of the ﬁrst
glycosylation site of PrP. This was achieved by inoculating G1
transgenic mice (that lack the ability to attach carbohydrates
to the ﬁrst glycosylation site of PrP; i.e., N180) with 79A or
ME7 TSE strains. G1 mice had an extended incubation time
when infected with 79A (þ 46 d) compared to wild-type mice
(Table 1) and a prominent difference in distribution and
degree of vacuolar pathology (Figure 3D). Brains of termi-
nally ill, 79A-infected G1 mice showed mono- and unglycosy-
lated PrPSc compared to di-, mono-, and unglycosylated PrPSc
Brain sections obtained from (A) clinically negative, or (B) clinically positive G3 mice after inoculation with 79A showing widespread accumulation of PrP
in the hippocampus and thalamus are shown.
(C and D) Brain sections from clinically negative G3 mice inoculated with ME7 showing large PrP positive plaques in subcallosal areas.
(E and F) Brain section of clinically positive 129/Ola mice infected with 79A (E) or ME7 (F), showing widespread PrP deposition in the hippocampus and
thalamus.
(G) Thioflavin-S fluorescent PrP-amyloid plaques in the subcallosal region of a clinically negative G3 mouse inoculated with 79A.
(H) Thioflavin-S treatment of sections from a clinically positive 129/Ola mouse infected with 79A with no presence of plaques.
(I) Thioflavin-S fluorescent PrP-amyloid plaques in a clinically negative G3 mouse infected with ME7.
(J) Thioflavin-S staining of a clinically positive 129/Ola mouse infected with ME7 with no presence of plaques.
Magnifications: (A), (B), (E), and (F): 43, (C), (G), (H), and (I): 103; and (D): 403.
doi:10.1371/journal.pbio.0060100.g002
Table 2. Second Passage of G2 and G3 Mouse Brain Inoculated with 79A; Incubation Periods of 129/Ola Mice
Host Genotype Inoculum Number Clinþ/Total Number of Animals Incubation Period (Days 6 SEM)
129/Ola 79A/G2a 11/11 150 (63.4)
129/Ola 79A/G2b 11/11 159 (61.2)
129/Ola 79A/129Ola 10/10 140 (61.9)
129/Ola 79A/G3a 12/12 197 (67.6)
129/Ola 79A/G3b 12/12 164 (62.2)
129/Ola 79A/129Ola 12/12 137 (61.1)
Incubation periods resulting from the passage of brain homogenate from 79A inoculated G2 (79A/G2), G3 (79A/G3) or wild-type (79A/129Ola) mice are shown. 79A/129Ola, 79A/G2a, 79A/
G2b, and 79A/G3a were from clinically positive and pathologically positive mice; 79A/G3b was from a clinically negative and pathologically positive mouse. The two 79A/129Ola control
groups are form the two different experiments: G2/79A second pass and G3/79A second pass.
doi:10.1371/journal.pbio.0060100.t002
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present in control 129/Ola mice (Figure 1F). Immunohisto-
chemical analysis revealed widespread PrP deposition in both
G1/79A and Wt/79A brain (Figure 6A, 6C, and 6E). However,
in striking contrast to infection with 79A, G1 mice inoculated
with ME7 appeared resistant to infection, remaining healthy
up to 600 days post-inoculation, whereas wild-type controls
had an incubation period of 163 6 2.0 d (Table 1). No PrPSc
was found by Western blot analysis in G1 brains inoculated
with ME7 (unpublished data). Moreover, pathologic studies
did not show PrP deposition or spongiform degeneration in
brains of G1 mice inoculated with ME7 (Figure 6B and 6D) in
sharp contrast to wild-type mice that showed wide spread PrP
accumulation in the brain (Figure 6F). These results again
indicate that TSE strains differ dramatically in their require-
ments for host PrP glycosylation.
Discussion
We have demonstrated in vivo that glycosylation of host
PrP is not necessary to establish a TSE. Mice expressing only
unglycosylated PrP (G3 mice) are capable of supporting a
TSE, albeit in a strain-dependant manner, but disease
susceptibility is reduced in response to the lack of glycans
on host PrP. This differs from a previous study that reported
that transgenic mice expressing unglycosylated PrP were
resistant to two TSE strains [3]. There are, however,
considerable differences between these two studies that may
account for the discrepancy including: (i) the expression of
hamster rather than mouse PrP genes, (ii) different TSE
strains, and (iii) the method of transgenic mouse production.
Gene targeting was used to generate the mice described in
this study, thus the altered PrP gene is in the normal
chromosomal location and under the PrP gene (Prnp) control
elements. Whereas a previous study by De Armond et al. used
transgenic mice generated by random integration of the PrP
transgene [3], which can result in disruption of genes at the
site of integration, ectopic expression due to the inﬂuence of
surrounding control elements, as well as high levels of
transgene expression, all of which may affect the outcome
of disease [14]. Indeed PrP glycosylation mutant transgenic
lines produced by random integration and expressing the
same transgene have been reported to display different
incubation periods with the same TSE strain, preventing
direct comparisons between different lines [17].
Our glycosylation-deﬁcient PrP transgenic mice have both
an alteration in amino acid sequence and glycosylation.
Mutation of either asparagine or threonine in the NXT
glycosylation consensus site of murine PrP will prevent the
attachment of glycans to asparagine. We altered asparagines
at both consensus sites to threonine, and this is regarded as a
conservative amino acid alteration. The PrP expressed in our
G1 and G2 transgenic lines is localised primarily at the cell
surface in a manner comparable to that in wild-type mice and
displays no detectable PrPSc-like properties as determined by
PK sensitivity, cleavability by phosphatidylinositol-speciﬁc
phospholipase C (PIPLC), and detergent solubility assays [13].
Moreover, remarkable similarity in the course of infection in
parts of this study argues against the substituted amino acids
affecting the course of disease but rather that the differences
observed can be attributed to differences in glycosylation.
The observation that G3 mice are capable of supporting
TSE disease is surprising given that the cellular location of
the unglycosylated PrP appears primarily intracellular [13].
This suggests that TSE disease can occur with perhaps
complete absence or at least very low levels of PrP on the
cell surface. 79A may be able to infect the cell via a
mechanism independent of cell surface expression of host
PrPC, suggesting that transit of normal PrP to the surface of
the cell [17,18] may not be an absolute requirement for the
Figure 3. Lesion Profile Analysis of TSE-Inoculated PrP Glycosylation Mutant Mice
G2 and 129/Ola mice were inoculated i.c. with TSE strains ME7 (A), 79A (B), or 301C (C) and G1 mice were inoculated i.c. with 79A (D). Squares: wild type;
open triangles: G2; and solid triangles: G1. All mice (12 in each group) used in these analyses were clinically and pathologically positive.
Nine gray matter areas: 1, dorsal medulla; 2, cerebellar cortex; 3, superior colliculus; 4, hypothalamus; 5, medial thalamus; 6, hippocampus; 7, septum; 8,
cerebral cortex; 9, forebrain cortex and three white matter areas: 1*, cerebellar white matter; 2*, mesencephalic tegmentum; 3*, pyramidal tract (x-axis)
were scored on scales of 0–5 for gray and 0–3 for white matter areas (y-axis). The mean scores for each area are shown (error bars 6 SEM). No
differences between wild-type and G2 mice were observed after inoculation with ME7 (A) or 79A (B); however some differences in the superior colliculus
and white matter areas were observed between the two groups when inoculated with 301C (C). Differences were observed between wild-type and G1
mice inoculated with 79A (D) especially in area: 2, 4, 8, and in the white matter.
doi:10.1371/journal.pbio.0060100.g003
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development of TSE disease. PrPSc accumulation in the TSE
infected animal is considered to occur through the inter-
action of PrPSc with host PrPC, resulting in conversion of
PrPC to PrPSc. We have established that glycosylation of host
PrP is not a requirement for the formation of de novo–
generated PrPSc in vivo, which is in agreement with in vitro
studies [19,20]. However, there is still uncertainty as to where
PrPC to PrPSc conversion occurs, with differing reports that it
takes place either at the cell surface, extracellularly, in
microsomes, along endocytic pathways, or in the cytosol [21–
25]. In our studies, the primarily intracellular location of the
unglycosylated PrP in G3 mice suggests that either the very
low levels of cell surface PrPC expression is adequate to allow
the conversion process to occur, or that conversion does not
Figure 4. Immunohistochemical Analysis of Brain from G2 Mice Inoculated with TSE Strains ME7, 79A, and 301C
Brain sections were immunostained for PrP using monoclonal antibody 6H4 and analysed by light microscopy using a Nikon Eclipse E 800 microscope.
Brains from clinically positive G2 mice inoculated with (A) ME7 or (B) 79A showing wide spread PrP deposition. Brains from 129/Ola wild-type mice
inoculated with (C) ME7 or (D) 79A also showing wide spread PrP deposition.
The TSE strain 301C was used to inoculate (E and F) G2 mice, which showed wide spread plaque-like and fine punctuate PrP deposits in the cerebrum and
cerebellum or (G and H) 129Ola mice, which also showed plaque-like PrP deposition. All 301C inoculated brains shown were from clinically positive mice.
Magnifications: (A–E) and (G), 43; (F) and (H), 103.
doi:10.1371/journal.pbio.0060100.g004
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occur at the cell surface; in vitro studies will be necessary to
resolve where conversion actually occurs in the G3 mice.
We have shown for the ﬁrst time, to our knowledge, that
glycosylation of PrPSc is not necessary for the transmission of
TSE infectivity to wild-type mice. This study also revealed
that the de novo PrPSc generated in the recipient animals
consisted of di-, mono-, and unglycosylated PrPSc, whereas
the donor PrPSc was fully unglycosylated. This is perhaps
surprising, considering it is postulated that the donor PrPSc
acts as a template for its ampliﬁcation [26], yet our results
suggest that the host dictates the glyscoylation status of the de
novo–generated PrPSc, rather than that of the donor as it has
also been suggested in some in vitro experiments [27,28]. The
effect of host on PrPSc glycosylation should therefore be
considered when glycoform analysis, which determines the
ratio of di- and monoglycosylated PrPSc, as well as the relative
mobility of unglycosylated PrPSc, is used to identify TSE
strains [29–31] and classify newly emerging ones [12,32].
In contrast to the results obtained using 79A, we found that
ME7 was unable to cause clinical TSE disease in mice
expressing only unglycosylated PrPC. G1 mice (which have
glycans only at N196) appear also resistant to TSE disease
following ME7 inoculation, whereas G2 mice are fully
susceptible to TSE disease with this strain. The fact that the
cellular location of PrPC in the G1 and G2 mice are
comparable to each other and to wild-type mice [13] indicates
that the inability of ME7 to cause TSE disease in the G1 mice
is not due to the cellular location of PrPC but rather due to
the absence of glycans at N180. Therefore, the inability of
ME7 to cause clinical TSE disease in G3 mice may also be due
to lack of carbohydrates at N180, rather than the low levels of
PrPC expressed at the cell surface.
G1 mice were found to be fully susceptible to TSE disease
following 79A inoculation, but with a prolonged incubation
time compared to wild-type mice. Similarly, the absence of
glycans at N196 resulted in a prolongation of incubation
period in 79A-inoculated G2 mice. With the cellular location
of PrP in G1 and G2 mice being comparable to that in wild-
type mice [13], perhaps the prolongation of incubation
period is due to the lack of glycans at N180 or N196,
respectively, but whether this is due to a reduced efﬁciency of
uptake, inefﬁcient interaction of the infectious agent with
PrPC due to the lack of glycans at either site, or a slightly
reduced efﬁciency of the disease process once the infectious
agent has gained access to cells can not be determined from
these studies. Experiments are underway to address this issue.
In contrast to the observation that the lack of glycans at N196
has little or no effect on TSE disease resulting from
inoculation with 79A or ME7, not all G2 mice inoculated
with the TSE strain 301C showed clinical signs of TSE disease,
and furthermore, those that did had a dramatic extension of
the incubation period. However, clinical TSE disease was
observed in the majority of 301C-inoculated mice, despite the
increase in incubation period, which indicates that this strain
does not have an absolute requirement for glycans at N196
but that the presence of them does allow for a more efﬁcient
infection.
Despite differences in susceptibility of G2 mice to infection
with three different strains, the vacuolation proﬁle of these
mice and wild-type mice was similar, suggesting that
glycosylation at the G2 site did not inﬂuence the strain
targeting. Contrastingly, the 79A vacuolation proﬁle in G1
was different when compared to wild type, indicating that
glycosylation at the G1 site may have an effect on strain
targeting. This ﬁnding will be further investigated in future
experiments.
Clinical negative G3 mice infected with 79A or ME7 have
shown the presence of PrP amyloid plaques in the brain. The
formation of amyloid plaques is commonly associated with
the pathological process of TSE disease as well as other
neurodegenerative diseases [33]. However an alternative view
Figure 5. Western Blot Analysis of Brains from Second Passage of 79A-
Infected G2 and Wild-Type Mice
Brain homogenates from (A) clinically and pathologically positive 79A
inoculated G2 or wild-type, 129/Ola (Wt), mice were used to i.c. inoculate
129/Ola mice.
(B) The 79A inoculated G2 mouse brains lacked diglycosylated PrPSc, but
all 129/Ola mice inoculated with 79A/G2 or 79A/Wt brain material had di-,
mono-, and unglycosylated PrPSc.
(C) Brain of a C57Bl mouse infected with 79A used as comparison for the
glycotype.
Brain homogenates from (D) clinically and pathologically positive ME7
inoculated-G2 or wild-type, 129/Ola (Wt), mice were used to intra-
cerebrally inoculate 129/Ola mice.
(E) The ME7 inoculated G2 mouse brains lacked diglycosylated PrPSc but
all 129/Ola mice inoculated with ME7/G2 or ME7/Wt brain material had
di-, mono-, and unglycosylated PrPSc.
(F) Brain of a C57Bl mouse infected with ME7 used as comparison for the
glycotype.
Lanes 1–6: TSE-inoculated 129/Ola mouse brain. All samples were PK
treated.
doi:10.1371/journal.pbio.0060100.g005
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is that plaque formation may actually be a mechanism that
the host uses to attempt to protect itself from the potentially
harmful effects of oligomers [34]. If this is the case in the TSE
diseases, then the lack of clinical disease in the majority of the
79A-infected G3 mice (despite the presence of TSE infectivity
as demonstrated by the transmission of TSE disease to wild-
type mice) could indicate that the host is attempting to
protect itself from the de novo generated abnormal PrP by
sequestering it as amyloid. Interestingly, PrP-amyloid plaques
have been detected previously in a transgenic mouse model
expressing mutant PrP in the absence of clinical signs,
spongiform degeneration, and infectivity [35]. Thus a possible
explanation for presence of plaques in clinical negative mice
may be that amyloid formation can somehow block the
propagation of disease within the brain. Our glycosylation
mutant transgenic mice may therefore provide a model to
investigate the involvement of PrP glycosylation on plaque
formation in response to different TSE strains.
In conclusion, we have demonstrated that glycosylation of
host PrP is not essential for the host to be susceptible to TSE
disease. Moreover, glycosylation of PrPSc is not necessary for
the transmission of TSE infectivity to a new host, and the
glycotype of the host PrP has a major inﬂuence on the de
novo generated PrPSc. Finally, we have shown that host PrP
has a major role to play in TSE disease susceptibility and
incubation period and that TSE strains differ dramatically in
their requirements for host PrP glycosylation in order to
allow TSE disease to occur.
Figure 6. Immunohistochemical Analysis of Brain from G1 Mice Inoculated with TSE Strains 79A and ME7
Brain sections were immunostained for PrP using monoclonal antibody 6H4 and analysed by light microscopy using a Nikon Eclipse E 800 microscope.
Widespread PrP immunopositivity is seen mostly in the thalamus (A and C) of clinically positive, symptomatic, G1 mice inoculated with 79A, absence of
PrP-immunopositivity in the hippocampus (B) and thalamus (D) of clinically (Clin) negative, asymptomatic, G1 mice inoculated with ME7, (E) widespread
PrP deposition in the thalamus and hippocampus of a wild-type mouse (129/Ola) after inoculation with 79A; (F) widespread PrP deposition in the
thalamus of a wild-type mouse with neurological signs after inoculation with ME7.
Magnifications: (A), (B), (E), and (F), 43; (C) and (D), 103.
doi:10.1371/journal.pbio.0060100.g006
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Materials and Methods
Transgenic mouse lines. Inbred gene targeted transgenic mouse
lines G1, G2, and G3, and the corresponding inbred 129/Ola wild-type
control line have been described previously [13]. All gene-targeted
transgenic mice used in this study were homozygous.
Genotyping of mouse tail DNA. A portion of tail was removed post-
mortem from each mouse. DNA was prepared from a 1-cm piece of
tail by digestion overnight at 37 8C in tail lysis buffer (300 mM sodium
acetate, 1% SDS, 10 mM Tris pH 8, 1 mM EDTA, 200 lg/ml PK) and
subsequent extraction with an equal volume of phenol/chloroform.
DNA was precipitated with isopropanol, washed with 70% ethanol,
and re-suspended in 100 ll of TE buffer (10 mM Tris, 1 mM EDTA pH
7.4). The mismatch PCR method to identify the different transgenics
has been described elsewhere [13].
Preparation of inoculum and injection. Inocula were prepared
from the brains of C57BL mice with terminal ME7, 79A, or 301C TSE
disease. A 1% homogenate of each sample was prepared in sterile
saline prior to use as an inoculum. All mice were genotyped by PCR,
grouped, and coded prior to intracerebral inoculation with 20 ll of
inoculum under anaesthesia. For second passage experiments,
separate inocula were prepared from the brains of two G2/79A
infected mice with terminal TSE disease as well as from the brain of
one 129/Ola (wild-type) mouse with terminal 79A scrapie as control. A
1% homogenate of each sample was prepared in sterile saline prior to
use as an inoculum for inoculation of 129/Ola wild-type mice. All
experimental protocols were submitted to the Local Ethical Review
Committee for approval before mice were inoculated. All experi-
ments were performed under license and in accordance with the UK
Home Ofﬁce Regulations (Animals (Scientiﬁc Procedures) Act 1986).
Scoring of clinical TSE disease. The presence of clinical TSE
disease was assessed as described previously [16]. Animals were scored
for clinical disease without reference to the genotype of the mouse.
Genotypes were conﬁrmed for each animal by PCR analysis of tail
DNA at the end of the experiment. Incubation times were calculated
as the interval between inoculation and cull due to terminal TSE
disease. Mice were killed by cervical dislocation at the terminal stage
of disease, at termination of the experiment (between 500–700 d), or
for welfare reasons due to intercurrent illness.
Lesion proﬁles. Sections were haematoxylin and eosin stained and
scored for vacuolar degeneration on a scale of 0 to 5 in nine standard
gray matter areas and a scale of 0 to 3 in three standard white matter
areas as described previously [16].
Immunohistochemistry. Sections were stained for disease associ-
ated PrP using monoclonal antibody 6H4 (1/10000; Prionics). Antigen
retrieval by autoclaving at 121 8C for 15 min, and 5 min formic acid
(98%) treatment was used to facilitate the detection of PrP. Sections
were then blocked with normal rabbit serum prior to incubation with
the primary antibody. Antibody binding was detected with the
Catalyzed Signal Ampliﬁcation System (Dakocytomation) and visual-
ized with diaminobenzidine (DAB). In all the experiments, normal
brain homogenate-infected and PrP-null negative controls were used.
Images were taken using a Nikon Eclipse E800 microscope. Sections
were analysed by an observer blinded to the mouse genotype and type
of inoculum.
Thioﬂavin-S treatment. Brain sections were stained with haema-
toxylin for 30 s and then washed in water. Sections were treated with
a thioﬂavin-s solution (10 mg/ml) for 5 min and then with a 70%
ethanol solution for 5 min. After washes with water, sections were
mounted using Fluorescent Mounting Medium (Dakocytomation) and
analysed using a Nikon Eclipse E400 microscope with a FITC ﬁlter.
Western blotting. Mice were killed by cervical dislocation and
brains and spleens were removed, ﬂash frozen in liquid nitrogen, and
then stored at 70 8C until required. Half or whole brains were
weighed and mechanically homogenized from frozen in nine volumes
of ice cold NP40 lysis buffer (1% Nonidet 40, 0.5% sodium
deoxycholate, 150 mM NaCl, 50 mM Tris pH 7.5), with the addition
of phenylmethysufonyl ﬂuoride (PMSF) (ﬁnal concentration 1lM;
Sigma) to prevent protein degradation by endogenous proteases. The
homogenate was centrifuged at 8000 revolutions per minute for 10
min to remove unhomogenised debris. Total protein was denatured
in 13 Novex Tris-Glycine SDS Sample Buffer (Invitrogen Life
Technologies) and 13 NuPage Sample Reducing Agent (Invitrogen
Life Technologies) for 30 min at 95 8C. Proteins were separated by gel
electrophoresis at 125 V using Novex Pre-cast Tris-Glycine gel (12%
or 14% acrylamide, Trisglycine; Invitrogen Life Technologies).
Proteins in the acrylamide gel were transferred to polyvinylindene
ﬂuoride (PVDF) membrane at 25 V (125 A/gel) using a semi-dry
transfer blotter (Bio-Rad) in 1X Transfer Solution (48 mM Tris, 39
mM Glycine, 0.375 % sodium dodecyl sulphate (SDS), 20% methanol).
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